Relmada Therapeutics Inc

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Relmada Therapeutics addresses setbacks, remains confident in REL-1017's potential

Relmada Therapeutics faced challenges in Q4 2022 with study results, leading to increased expenses and a net loss. Despite setbacks, the company remains confident in REL-1017's potential and is focused on refining trial protocols for future success.

Relmada Therapeutics reports positive Q1 results and advances MDD treatment

Relmada Therapeutics Inc. demonstrates financial improvement and progress in its REL-1017 program for major depressive disorder. The company's strategic amendments to study protocols and upcoming safety study data release indicate a commitment to advancing its pipeline. Addressing challenges in trial management and regulatory interactions is key to sustaining growth and market success.

Relmada Therapeutics reports improved Q2 financials and advances in key trials

Relmada Therapeutics showcased improved financial performance and progress in key clinical trials during the Q2 2023 Earnings Call.
While challenges like enrollment progress and regulatory feedback exist, the company's adaptability and cash position provide strengths to navigate them.
Opportunities lie in expanding the clinical program, achieving positive trial outcomes, and enhancing investor confidence through transparent communication.

Relmada Therapeutics reports positive Q3 results and advances key programs

Relmada Therapeutics demonstrated strong performance in Q3 2023 with progress in key programs and improved financial metrics.
While facing challenges in expense management and trial timelines, the company's strengths in research and financial discipline position them well for future growth.
Opportunities lie in leveraging positive trial results, attracting investors, and advancing innovative treatments to drive value creation.

Relmada Therapeutics reports progress in Phase III programs and financial stability

Relmada Therapeutics Inc showcased positive performance in its Phase III program and financial results, demonstrating resilience and strategic planning. While challenges exist in enrollment and monitoring, the company's confidence in its products and innovative approach to psilocybin present promising opportunities for growth and development.

Relmada Therapeutics Inc reports strong Q1 performance and pipeline advancements

Relmada Therapeutics Inc reported positive financial performance, progress in key programs, and proactive pipeline expansion in Q1 2024, positioning the company for future growth.
While facing challenges such as increased screening failure rates and competition, Relmada's strategic focus on trial optimization and therapeutic innovation presents opportunities for advancement.
The company's commitment to addressing mental health needs through Phase III trials and novel programs like psilocybin underscores its dedication to driving clinical progress and market differentiation.
With a strong financial position and promising developments in the pipeline, Relmada is poised to navigate challenges, capitalize on opportunities, and drive value for stakeholders.

Relmada Therapeutics advances CNS disorder treatments amidst financial stability

Relmada Therapeutics is making strides in advancing treatments for CNS disorders, with a focus on major depressive disorder. Financially, the company is managing expenses while progressing key programs. Uncertainty around interim analysis outcomes presents challenges, but successful results could open doors to new opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics Inc (NASDAQ: RLMD) has announced positive top-line results from the human abuse potential (HAP) study with REL-1017 for major depressive disorder (MDD).  Top-line results showed that all three doses of REL-1017 (25 mg, 75 mg, and 150 mg) tested in recreational opioid users demonstrated a highly statistically significant difference vs.

Relmada's Stock Moves Higher As Its Major Depressive Disorder Candidate Shows Lack Of Abuse Potential

NEW YORK, July 27, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today top-line results of the human abuse potential (HAP) study with REL-1017, a novel NMDA receptor (NMDAR) channel blocker and the company's lead candidate in Phase 3 development for the treatment major depressive disorder (MDD).   Top-line results showed that all three doses of REL-1017 (25 mg, 75 mg and 150 mg, the therapeutic, supratherapeutic and maximum tolerated doses, respectively) tested in recreational opioid users, demonstrated a highly statistically significant difference vs.

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential

Relmada Therapeutics Inc (NASDAQ: RLMD) has acquired the development and commercial rights to novel psilocybin and derivate program from Arbormentis LLC in all ex-Asia territories, including the U.S. and Europe.  Relmada will collaborate with Arbormentis to develop new therapies targeting neurological and psychiatric disorders.

Relmada Therapeutics In-Licenses Psilocybin Program From Arbormentis

NEW YORK, July 20, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the acquisition of development and commercial rights to a novel psilocybin and derivate program from Arbormentis LLC in all ex-Asia territories, including the U.S. and Europe.  Relmada will collaborate with Arbormentis on the development of new therapies targeting neurological and psychiatric disorders, leveraging its understanding of neuroplasticity, and focusing on this emerging new class of drugs targeting the neuroplastogen mechanism of action.

Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC

NEW YORK, June 15, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data related to REL-1017, the company's lead product candidate, will be presented in two poster presentations at the College on Problems of Drug Dependence (CPDD) 83rd Annual Meeting, which will be held virtually between June 21 through June 24, 2021. Both presentations will take place on June 21, 2021, from 3:00 – 4:00 PM ET, during Session I.

Relmada Therapeutics to Present Data at the College on Problems of Drug Dependence 83rd Annual Scientific Meeting

NEW YORK, June 7, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer of Relmada, is scheduled to participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021at 8:00 a.m. Eastern Time.

Relmada Therapeutics Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference

NEW YORK, June 1, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer of Relmada, is scheduled to participate in a fireside chat at Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 10:30 am Eastern Time. Participants may access a live webcast of the event through the following link: https://wsw.com/webcast/jeff174/rlmd/1853145  The webcast can also be accessed in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.

Relmada Therapeutics Announces Participation in Jefferies Virtual Healthcare Conference

NEW YORK, May 26, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that clinical data related to REL-1017, the company's lead product candidate, will be presented in a live oral poster presentation at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, which is being held virtually between June 1 and June 4, 2021. Details of the virtual oral presentation are as follows: Title: REL-1017 (esmethadone) is Safe, Well-Tolerated and Exerts Rapid, Robust and Sustained Antidepressant Effects as Adjunctive Treatment in Patients with Major Depressive Disorder: a Phase 2 Double Blind Randomized Trial  Presenter: Marco Pappagallo, MD, Chief Medical Officer of Relmada Therapeutics Session Title: Pharmaceutical Pipeline Session Date and Time:  Tuesday, June 1, 2021, from 2:45 – 4:45 PM ET About REL-1017 REL-1017, a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development as an adjunctive treatment for MDD in adults.

Relmada Therapeutics Announces Oral Poster Presentation on REL-1017 at 2021 American Society of Clinical Psychopharmacology Annual Meeting

Relmada Therapeutics, Inc. (RLMD) CEO Sergio Traversa on Q1 2021 Results - Earnings Call Transcript

NEW YORK, May 12, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced financial results for the first quarter ended March 31, 2021. "We continue to advance the development of our lead product candidate, REL-1017, for the treatment of major depressive disorder (MDD)," said Sergio Traversa, Relmada's Chief Executive Officer.

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results

NEW YORK, May 6, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2021 after the market close on Wednesday, May 12, 2021. The company will host a corporate update conference call and live audio webcast at 4:30 PM Eastern Time on Wednesday, May 12, 2021.

Relmada Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 12, 2021

NEW YORK, May 1, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that clinical data related to REL-1017, the company's lead product candidate, will be presented in two posters at the American Psychiatric Association (APA) Annual Meeting 2021, which is being held virtually between May 1 and May 3, 2021. Details of the poster presentations are below: Date/Time: May 1, 2021, from 1:00 – 1:30 PM ET Poster Number: 5181 Title: Rapid and Sustained Antidepressant Effects of REL-1017 (esmethadone) as an Adjunctive Treatment for Major Depressive Disorder: A Phase 2 Trial  Date/Time: May 1, 2021, from 1:00 – 1:30 PM ET Poster Number: 5198 Title: Effect of Percentage of Life-Years from the Start of Major Depressive Disorder on the Therapeutic Response of REL-1017  The on-demand posters are available for viewing online for the duration of the meeting by registered conference attendees.

Relmada Therapeutics Announces Poster Presentations at the American Psychiatric Association Annual Meeting 2021

NEW YORK, April 29, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data related to REL-1017, the company's lead product candidate, will be presented in six posters at the 2021 Society of Biological Psychiatry (SOBP) Annual Meeting, which is being held virtually between April 29 and May 1, 2021. Details of the presentations are below: Date/Time: April 29, 2021, from 1:15 – 2:15 PM ET Poster Number: T142 Title: Esmethadone (REL-1017) Antagonizes NMDA Receptors and Reduces Ca2+ Entry in Presence of Quinolinic Acid and Gentamicin  Session: Poster Session I Date/Time: April 29, 2021, from 1:15 – 2:15 PM ET Poster Number: T143 Title: Esmethadone (REL-1017) Reduces Glutamate-Induced Currents in NMDA Receptors with the GluN2D Subunit Session: Poster Session I Date/Time: April 30, 2021, from 1:00 – 2:00 PM ET Poster Number: F136 Title: Esmethadone (REL-1017) Compares with NMDA Receptor Antagonists in FLIPR Ca2+ Assay  Session: Poster Session II Date/Time: April 30, 2021, from 1:00 – 2:00 PM ET Poster Number: F137 Title: Esmethadone (REL-1017) Shows Similar Effects to Ketamine in Manual Patch Clamp Studies Session: Poster Session II Date/Time: May 1, 2021, from 1:30 – 2:30 PM ET Poster Number: S138 Title: Esmethadone (REL-1017) Restores NMDA Receptor 1 Subunit Expression in an In Vitro Model of Glutamatergic Excitotoxicity  Session: Poster Session III Date/Time: May 1, 2021, from 1:30 – 2:30 PM ET Poster Number: S143 Title: Esmethadone (REL-1017) Reduces Glutamate-Induced Currents in NMDA Receptors in a Concentration Dependent Manner Session: Poster Session III About REL-1017 REL-1017, a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is entering late-stage studies as an adjunctive treatment for MDD in adults.

Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting

NEW YORK, April 28, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer of Relmada, is scheduled to participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on Tuesday, May 4, 2021 at 2:40 pm Eastern Time. A live webcast of the fireside chat will be available at https://kvgo.com/life-sciences-summit/relmada-therapeutics-inc-may-2021 and via the investor section of the Company's website.

Relmada Therapeutics Announces Participation in the 7th Annual Truist Securities Life Sciences Summit

NEW YORK, April 27, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data related to REL-1017, the company's lead product candidate, will be presented in a poster at the American Society for Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting at Experimental Biology (EB) 2021, which is being held virtually between April 27 and April 30, 2021. Details of the presentation are below: Poster Number: R2195 Title: REL-1017 (esmethadone) Did Not Produce Initial or Cumulative Neurotoxic Effects or Other Evidence of Damage to Cortical Neurons The abstract is available on the meeting website and the poster is also available online to registered attendees from April 13 to May 31, 2021.

Relmada Therapeutics Announces Poster Presentation at the American Society for Pharmacology and Experimental Therapeutics Annual Meeting at Experimental Biology 2021

NEW YORK, April 1, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the initiation of the second of the two sister pivotal Phase 3 clinical trials (RELIANCE I and RELIANCE II) for the Company's lead product candidate, REL-1017, as an adjunctive treatment for major depressive disorder (MDD). "We are pleased to begin enrolling patients into the second Phase 3 clinical trial of REL-1017 in MDD, a condition impacting more than 17 million individuals in the U.S., with limited safe and effective therapeutic options currently available," said Sergio Traversa, Relmada's Chief Executive Officer.

Relmada Therapeutics Announces Initiation of Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder

Relmada Therapeutics, Inc. (RLMD) CEO Sergio Traversa on Q4 2020 Results - Earnings Call Transcript

NEW YORK, March 23, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced financial results for the fourth quarter and full-year ended December 31, 2020. "We have achieved significant progress in advancing our lead product candidate, REL-1017, which has the potential to be the first U.S. Food and Drug Administration (FDA)-approved anti-depressant for adjunctive treatment of major depressive disorder (MDD)," said Dr. Sergio Traversa, Relmada's Chief Executive Officer.

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results

NEW YORK, March 18, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2020 after the market close on Tuesday, March 23, 2021. The company will host a corporate update conference call and live audio webcast at 4:30 PM Eastern Time on Tuesday, March 23, 2021.

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on March 23, 2021

NEW YORK, March 11, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer of Relmada, will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021 at 10:40 a.m. Eastern Time.

Relmada Therapeutics Announces Participation in the Oppenheimer 31st Annual Healthcare Conference

Investors need to pay close attention to Relmada (RLMD) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Relmada (RLMD) Stock?

NEW YORK, Dec. 7, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that the first patient has been enrolled in the first Phase 3 clinical trial (RELIANCE I) for the...

Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder

AstraZeneca

Biogen

Momenta Pharmaceuticals

Neoleukin Therapeutics Inc

Perrigo

Sanofi

Supernus Pharmaceuticals

Takeda Pharmaceutical

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.

Top Pharmaceutical Stocks for Q4 2020

NEW YORK, Aug. 31, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Relmada Therapeutics, Inc.

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Relmada Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

DURECT

Relmada Therapeutics, Neoleukin Therapeutics, and Durect were among the fastest-rising pharmaceutical stocks over the past year.

News for Relmada Therapeutics Inc Stock (RLMD)